Mosaic ImmunoEngineering (CPMV) Common Equity (2011 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Common Equity of -$7.7 million for Q1 2026, down 9.78% year-over-year from -$8.5 million in Q1 2025, and down 2.35% quarter-over-quarter from -$7.5 million in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Common Equity (2011 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Common Equity history runs 16 years deep, the most recent figure standing at -$7.7 million for Q1 2026.
- In Q1 2026, Common Equity fell 9.78% year-over-year to -$7.7 million; the TTM figure through Mar 2026 stood at -$7.7 million (down 9.78% YoY), while the FY2025 annual figure was -$7.5 million, down 10.13% from the prior year.
- Common Equity for Q1 2026 stood at -$7.7 million, down from -$7.5 million in the prior quarter.
- The five-year high for Common Equity was -$3.4 million in Q1 2022, with the low at -$7.7 million in Q1 2026.
- The 5-year median for Common Equity is -$6.2 million (2024), against an average of -$6.0 million.
- The sharpest annual moves came in 2022 and 2026: Common Equity tumbled 258.43% in 2022, then slipped 9.78% in 2026.
- Mosaic ImmunoEngineering's Common Equity stood at -$4.9 million in 2022, then declined by 20.19% to -$5.9 million in 2023, then retreated by 15.62% to -$6.8 million in 2024, then retreated by 10.13% to -$7.5 million in 2025, then slipped by 2.35% to -$7.7 million in 2026.
- Business Quant data shows CPMV's Common Equity at -$7.7 million in Q1 2026, -$7.5 million in Q4 2025, and -$7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Mosaic ImmunoEngineering | 527,536.97 | 527,536.97 | - | -7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.65 Mn |
| Dec 31, 2025 | -7.48 Mn |
| Sep 30, 2025 | -7.31 Mn |
| Jun 30, 2025 | -7.14 Mn |
| Mar 31, 2025 | -6.97 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -6.64 Mn |
| Jun 30, 2024 | -6.45 Mn |
| Mar 31, 2024 | -6.15 Mn |
| Dec 31, 2023 | -5.87 Mn |
| Sep 30, 2023 | -5.58 Mn |
| Jun 30, 2023 | -5.25 Mn |
| Mar 31, 2023 | -5.28 Mn |
| Dec 31, 2022 | -4.88 Mn |
| Sep 30, 2022 | -4.36 Mn |
| Jun 30, 2022 | -4.26 Mn |
| Mar 31, 2022 | -3.42 Mn |
| Dec 31, 2021 | -2.80 Mn |
| Sep 30, 2021 | -2.20 Mn |
| Jun 30, 2021 | -1.51 Mn |